Smarter MRI to reduce unnecessary prostate biopsies
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new computer program that combines MRI and other health information to better decide if a prostate biopsy is needed, which could help avoid unnecessary procedures for men with a possible prostate concern.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a Chinese man aged 50 or older.
- You must have a raised PSA level (over 4) or an abnormal digital rectal exam or other test result, which has led your doctor to suggest a prostate biopsy.
- You must not have had a previous prostate biopsy or treatment for prostate cancer.
- You must not have had any prior cancer of the urinary or reproductive system.
- You must have complete and good-quality MRI scans and other medical records.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether artificial intelligence can better predict prostate cancer by combining two types of scans (MRI and PSMA PET) along with your medical history, PSA, and biopsy results. If you have already had these scans and a biopsy, your information may help researchers develop a more accurate, non-invasive diagnostic tool.
This trial tests if using MRI and a blood test called PHI can help decide who needs a prostate biopsy. It aims to avoid unnecessary biopsies while still catching cancer early.
This study tests an artificial intelligence (AI) tool that may improve how doctors detect prostate cancer using imaging and biopsy information. It could help better identify cancer that is suspected based on PSA blood tests and rectal exam findings.
This study tests if a special MRI measurement (ADC) can improve how well a standard MRI finds prostate cancer. If you have a suspicious MRI and are scheduled for a biopsy, this might help better understand your results.
This trial tests whether an artificial intelligence (AI) program can help doctors decide when a prostate biopsy is needed. It is for men who have had a prostate MRI that shows either a low-risk (PIRADS 1-2) or uncertain (PIRADS 3) spot, along with a higher-than-normal PSA level. You may qualify if you have certain risk factors like a high PSA density, suspicious digital rectal exam, or family history of prostate cancer.
This trial tests a new calibration technology to improve how suspicious spots seen on MRI are targeted during prostate biopsy. It may help men who need a biopsy after an MRI shows a possible cancer area (Likert 3 or higher).
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.